TSN 0.00% 1.0¢ the sustainable nutrition group ltd

ha-irinotecan phase 3 trial update , page-3

  1. 375 Posts.
    Positive

    "The expectation for this study, based on our prior clinical experience, is that HA-Irinotecan will provide improved clinical benefit to patients without increasing the burden of toxicity. While it is still early in the trial, the data presented to the DSMB is consistent with that expectation.”


    Negative

    slow recruitment
 
watchlist Created with Sketch. Add TSN (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.